以下资料仅供本校师生阅读，不得下载！

Microenvironment in Tumor Biology

• Microenvironment in Tumor Biology
• Gene–environment interaction in tobacco-related cancers
• Adaptation to hypoxia and acidosis in carcinogenesis and tumor progression
• bi-mi-Value of the electronic patient record
• Can cancer be reversed by engineering the tumor microenvironment
• Cancer development at tissue level
• Carcinogenesis in Down syndrome
• Chromatin Organization and Nuclear Microenvironments in Cancer Cells
• Genetic and epigenetic regulation in nuclear microenvironments for biological control in cancer
• Invasion emerges from cancer cell adaptation to competitive microenvironments
• Macrophage polarization in tumour progression
• Nuclear microenvironment in cancer diagnosis and treatment
• Nuclear microenvironments and cancer
• Nuclear structure as a source of cancer specific biomarkers
• The cancer nuclear microenvironment
• The microenvironments of multistage carcinogenesis
• Theories of carcinogenesis
• Unraveling the microenvironmental influences on the normal mammary gland and breast cancer
• Using microarrays to study the microenvironment in tumor biology

back

Hyaluronan in Cancer Biology

• Hyaluronan in Cancer Biology: Editorial
• Altered hyaluronan biosynthesis in cancer progression
• Association between cancer and acid mucopolysaccharides
• Hyaluronan in human tumors
• Hyaluronan-A constitutive regulator of chemoresistance and malignancy in cancer cells
• Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression
• Hyalurondiase-Both a tumor promoter and suppressor
• Hyaluronidase 2 and its intriguing role as a cell-entry receptor for oncogenic sheep retroviruses
• Hyaluronidases in cancer biology
• Involvement of CD44, a molecule with a thousand faces, in cancer dissemination

back

Myeloid disease

• Myeloid disease-EDITORIAL COMMENT
• Alternative donor transplants for high-risk acute myeloid
• Exploiting the mammalian target of rapamycin pathway in hematologic malignancies
• Integration of monoclonal antibodies and immunoconjugates into the treatment of acute myeloid leukemia
• Monitoring minimal residual disease in patients with chronic myeloid leukemia
• New insights into the pathogenesis and treatment of chronic myeloproliferative disorders
• New molecular concepts and targets in acute myeloid leukemia
• Novel strategies for relapsed and refractory acute myeloid leukemia
• Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia
• Who with chronic myelogenous leukemia to transplant in the era of tyrosine kinase inhibitors
• Alternative donor transplantation in acute myeloid leukemia
• Evolving classifications of the myelodysplastic syndromes
• Hematopoietic cell transplantation after reduced-intensity conditioning for older adults with acute myeloid leukemia in complete remission
• Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia
• Insight into the molecular pathogenesis of myeloid malignancies
• Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase
• Progress and strategies for patients with relapsed and refractory acute myeloid leukemia
• The diagnostic interface between histology and molecular tests in myeloproliferative disorders
• The role of HOX genes in malignant myeloid disease
• The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes
• Umbilical cord blood transplantation for myeloid malignancies

back

The Thioredoxin System in Cancer

• -Thioredoxin in cancer—Role of histone deacetylase inhibitors
  
• -Thioredoxin and protein kinases in redox signaling
  
• -The thioredoxin system in cancer—introduction to a thematic volume of Seminars in Cancer Biology
  
• -The thioredoxin system in cancer
  
• -On the potential of thioredoxin reductase inhibitors for cancer therapy
  
• -Motexafin gadolinium-A novel redox active drug for cancer therapy
  
• -Extracellular thioredoxin and thioredoxin-binding protein 2 in control of cancer
  

back

Oncogenes and MicroRNAs

• Viruses, microRNAs and cancer
  
• Tumour-related microRNAs functions in Caenorhabditis elegans
  
• Principles of micro-RNA production and maturation
  
• Principles and effects of microRNA-mediated post-transcriptional gene regulation
  
• miRNAs and apoptosis
  
• MicroRNAs and the hallmarks of cancer
  
• MicroRNAs and chromosomal abnormalities in cancer cells
  
• MicroRNAs and cancer
  
• Implications of micro-RNA profiling for cancer diagnosis
  
• A small piece in the cancer puzzle
  

back

Natural killer cells in cancer

• Tumor and viral recognition by natural killer cells receptors
• The role of the NKG2D receptor for tumor immunity
• The role of NK cell recognition of nectin and nectin-like proteins in tumor immunosurveillance
• The dynamics of natural killer cell tolerance
• The DNA damage response, immunity and cancer
• Positive and negative regulation of Natural Killer cells
• NK cell activating ligands on human malignant cells
• Natural killer cells in cancer
• atural killer cell recognition of missing self and haploidentical hematopoietic transplantation

back

Mitochondria in cancer

• The many shapes of mitochondrial death
• Succinate dehydrogenase and fumarate hydratase
• p53 and Nur77-TR3 – transcription factors that directly target mitochondria for cell death induction
• Mitochondriotoxic compounds for cancer therapy
• Mitochondrial mutations in cancer
• Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt
• Mitochondrial factors with dual roles in death and survival
• Mitochondrial DNA mutations in human cancer
• Mitochondria in hematopoiesis and hematological diseases
• Mitochondria in cancer
• Mitochondria in cancer.
• Mitochondria as therapeutic targets for cancer chemotherapy
• Mitochondria and cancer
• Hexokinase II-Cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria
• he permeability transition pore complex in cancer cell death
• Glycolysis inhibition for anticancer treatment
• Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy
• Contribution of somatic mutations in the mitochondrial genome to the development of cancer and tolerance against anticancer drugs

back

Cancer in AIDS

• Update in HIV lymphoma
• The growing problem of non-AIDS-defining malignancies in HIV
• Signal transduction targets in Kaposi's sarcoma
• Pathogenesis of AIDS lymphoma
• Human papillomavirus-related tumors in HIV
• Challenges and opportunities for treatment and research of AIDS-related malignancies in Africa

back

160 Years of Multiple Myeloma-Progress and Challenges

• The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma
• The role of anatomic and functional staging in myeloma
• Thalidomide and lenalidomide in the treatment of multiple myeloma
• State of the art therapy in multiple myeloma and future perspectives
• Signalling and survival pathways in multiple myeloma
• Proteasome inhibition in multiple myeloma
• Progress and Challenges-Epidemiology and outcomes research for MGUS, myeloma and amyloidosis
• Myeloma bone disease and treatment options
• Multiple myeloma-Monoclonal antibodies-based immunotherapeutic strategies and targeted radiotherapy
• Genetics and molecular profiling of multiple myeloma
• Familial risks and temporal incidence trends of multiple myeloma
• Cytogenetics and molecular cytogenetics in multiple myeloma
• Conventional diagnostics in multiple myeloma
• Bone markers in multiple myeloma
• Angiogenesis in multiple myeloma
• An update-Health economics of managing multiple myeloma
• Allogeneic haematopoietic cell transplantation for multiple myeloma
• Active immunotherapy of multiple myeloma
• 160 years of multiple myeloma

back

肿瘤与DNA甲基化

• The promise of epigenetic therapy
• X marks the spot
• Transcription — guarding the genome by sensing DNA damage
• The theoretical basis of transcriptional therapy of cancer
• The prima donna of epigenetics-the regulation of gene expression by DNA methylation
• The power and the promise of DNA methylation markers
• The history of cancer epigenetics
• The fundamental role of epigenetic events in cancer
• The epigenome as a molecular marker and target
• Targeted modulation of MGMT
• Silent transmission
• Repairing DNA-methylation damage
• Promoter methylation and inactivation of tumour-suppressor genes in oral squamous-cell carcinoma
• On the biological significance of DNA methylation
• MGMT-its role in cancer aetiology and cancer therapeutics
• Methylation of the tumor suppressor gene RASSF1A in human tumors
• Methyl-CpG-binding proteins in cancer
• Inhibitors of DNA methylation
• Genomic DNA methylation
• Gene-promoter hypermethylation as a biomarker in lung cancer
• Folate and prevention of colorectal cancer
• Epigenetics provides a new generation of oncogenes and tumour-suppressor genes
• epigenetics makes the difference
• Epigenetic silencing of the MGMT gene in cancer
• Epigenetic mechanisms of tumorigenesis
• Epigenetic mechanisms in memory formation
• Epigenetic events in the colorectum and in colon cancer
• Enzymatic DNA methylation is an epigenetic control for genetic functions of the cell
• DNA methyltransferase inhibitors and the development of epigenetic cancer therapies
• DNA methylation-its role in lung carcinogenesis and therapeutic implications
• DNA methylation in neuroblastic tumors
• DNA methylation disturbances as novel therapeutic target in lung cancer
• DNA methylation and human disease
• DNA methylation and gene silencing in cancer
• DNA methylation and demethylation as targets for anticancer therapy
• DNA demethylation and carcinogenesis
• Detection and interpretation of altered methylation patterns in cancer cells
• CpG island methylator phenotype in cancer
• CpG island hypermethylation in progression of esophageal and gastric cancer
• Combined targeting of the epigenetic silence in leukemia
• Chromatin modifier enzymes, the histone code and cancer
• Causes and consequences of DNA hypomethylation in human cancer
• Aberrant methylation of H-cadherin (CDH13) promoter is associated with tumor progression in primary nonsmall cell lung carcinoma
• CA-EPIGENETICS-DNA methylation－EPIGENETICS-DNA methylation

back

Small Cell Lung Cancer

• Non–Small Cell Lung Cancer
• An Update on the Role of Epidermal Growth Factor Receptor Inhibitors in Non–Small Cell Lung Cancer
• Use of Novel Second-Line Targeted Therapies in Non–Small Cell Lung Cancer
• Targeting Angiogenesis in Lung Cancer
• Second-Line Treatment Options in Non–Small Cell Lung Cancer
• Second-Line Treatment Options in Advanced Non–Small Cell Lung Cancer
• Role of Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors
• Other Compounds and Targets in Non–Small Cell Lung Cancer
• Optimizing Therapy in Previously Treated Non–Small Cell Lung Cancer
• Ongoing First-Line Studies of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
• Geographic Variation in the Second-Line Treatment of Non–Small Cell Lung Cancer
• Future Directions in the Second-Line Treatment of Non–Small Cell Lung Cancer
• Emergence of a Unique Population in Non–Small Cell Lung Cancer

back

Prevention and Management of Prostate Cancer

• Challenges and Future Directions in the Prevention and Management of Prostate Cancer
• Versus Delayed Androgen Deprivation for Prostate Cancer
• Utility of Prostate-Specific Antigen Kinetics in Addition to Clinical Factors in the Selection of Patients for Salvage Local Therapy
• The Changing Face of Prostate Cancer
• Should Intermittent Androgen Deprivation Be Used in Routine Clinical Practice
• Role of Salvage Radical Prostatectomy for Recurrent Prostate Cancer After Radiation Therapy
• Role of Diet in Prostate Cancer Development and Progression
• Robotic-Assisted Laparoscopic Prostatectomy
• Radiotherapy in the Management of Clinically Localized Prostate Cancer
• Phase III Prostate Cancer Prevention Trials
• Pathogenesis and Treatment of Prostate Cancer Bone Metastases
• Parameters for Treatment Decisions for Salvage Radiation Therapy
• Management of Advanced Prostate Cancer After First-Line Chemotherapy
• High-Risk Localized Prostate Cancer
• Chemotherapy for Hormone-Refractory Prostate Cancer
• Bisphosphonates for Treatment and Prevention of Bone Metastases
• Active Surveillance for Prostate Cancer

back

Hematologic Malignancies

• Treatment Strategies in Follicular Lymphomas
• Targeting Histones and Proteasomes-New Strategies for the Treatment of Lymphoma
• State-of-the-Art Therapeutics
• State-of-the-Art Therapeutics-Marginal-Zone Lymphoma
• State-of-the-Art Therapeutics-Hodgkin's Lymphoma
• State-of-the-Art Therapeutics-Diffuse Large B-Cell Lymphoma
• Prognostic and Therapeutic Significance of Myeloma Genetics and Gene Expression Profiling
• Pathogenesis of Mantle-Cell Lymphoma
• Novel Immune-Based Treatment Strategies for Chronic Lymphocytic Leukemia
• New Targeted Approaches in Chronic Myeloid Leukemia
• Molecular Pathogenesis of Mucosa-Associated Lymphoid Tissue Lymphoma
• Molecular Pathogenesis of Hodgkin's Lymphoma
• Molecular Pathogenesis of Follicular Lymphoma
• Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma
• Molecular Pathogenesis and a Consequent Classification of Multiple Myeloma
• Molecular Genetics of Acute Lymphoblastic Leukemia
• Immunotherapy for Non-Hodgkin's Lymphoma
• Identification and Validation of Novel Therapeutic Targets for Multiple Myeloma
• Genetics of Myeloid Malignancies
• Gene Expression Profiling in Acute Myeloid Leukemia
• Current Treatment Approaches for Mantle-Cell Lymphoma

back

Gastrointestinal Tract CANCER

• Hepatic Resection-The Last Surgical Frontier for Colorectal Cancer
• Systemic Therapy for Metastatic Colorectal Cancer
• Role of Genomic Markers in Colorectal Cancer Treatment
• Role of Endoscopic Ultrasonography in the Staging and Follow-Up of Esophageal Cancer
• Optimal Locoregional Treatment in Gastric Cancer
• Molecular Markers of Early Pancreatic Cancer
• Locally Advanced Pancreatic Cancer
• Intraductal Papillary Mucinous Tumors of the Pancreas
• Endoscopic Techniques to Diagnose and Manage Biliary Tumors
• Endoscopic Mucosal Resection for Early Cancers of the Upper Gastrointestinal Tract
• Does Screening for Barrett's Esophagus and Adenocarcinoma of the Esophagus Prolong Survival
• Development of Cell Cycle Active Drugs for the Treatment of Gastrointestinal Cancers
• Adjuvant Treatment for Resectable Pancreatic Cancer

back

Polymorphisms and Cancer

• Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer
• Thiopurine S-methyltransferase pharmacogenetics-insights, challenges and future directions
• Polymorphisms in the p53 pathway
• Pharmacogenetics of human cytosolic sulfotransferases
• N-acetyltransferase 2 genetic polymorphism
• Mouse models of XRCC1 DNA repair polymorphisms and cancer
• Glutathione S-transferase polymorphisms
• Cyclin D1-polymorphism, aberrant splicing and cancer risk

back

Gastric Cancer and Helicobacter pylori

• Introduction-What Should We Do Now about H. pylori
• Vaccination as a method of preventing Helicobacter pylori-associated gastric cancer
• Trends in Helicobacter pylori Infection and Gastric Cancer in Mexico
• Tobacco Use and Stomach Cancer in Mizoram, India
• The Development of Therapeutic and Preventive Vaccines for Gastric Cancer and Helicobacter pylori
• The biology of Helicobacter pylori infection, a major risk factor for gastric adenocarcinoma
• Molecular analysis of B-cell clonality in Helicobacter pylori gastritis
• Immunity markers in patients with Helicobacter pylori infection
• Host-Environment Interactions-Their Impact on Progression from Gastric Inflammation to Carcinogenesis and on Development of New Approaches to Prevent and Treat Gastric Cancer
• Helicobacter pylori seroprevalence in patients with coronary artery disease
• Helicobacter pylori infection and gastric mucosal epithelial cell apoptosis
• Helicobacter pylori eradication has the potential to prevent gastric cancer
• Helicobacter pylori endemic and gastric disease
• Helicobacter pylori and Gastric Cancer
• Etiology of Gastric Cancer

back

Cancer and inflammation

• cancer and inflammation
• Cancer CXC chemokine networks and tumour angiogenesis
• C-reactive protein levels and subsequent cancer outcomes
• Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression
• Tumour necrosis factor-α as a tumour promoter
• Therapeutic potential of cytokine and chemokine antagonists in cancer therapy
• NF-κB inhibition
• Is nuclear factor kappa-B the missing link between inflammation, cancer and alteration in hepatic drug metabolism in patients with cancer
• Inflammatory chemokines in cancer growth and progression
• Inflammation, proteases and cancer
• Inflammation in epithelial skin tumours
• Helicobacter pylori infection and gastric cancer
• Endometriosis as a model for inflammation–hormone interactions in ovarian and breast cancers
• Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour–host interactions

back

Oncogenes and cell proliferation

• Oncogenes and cell proliferation Shifting paradigms in the understanding and treatment of cancer
• Transforming science
• Targeted CML therapy
• Stem cells in the etiology and treatment of cancer
• Specific peptides for the therapeutic targeting of oncogenes
• Release and trafficking of lipid-linked morphogens
• p63-oncogene or tumor suppressor
• mTOR and cancer
• MicroRNAs as oncogenes
• Matrix metalloproteinase-induced genomic instability
• Invasion is a genetic program regulated by transcription factors
• Inhibition of TGFβ signaling in cancer therapy
• Drosophila models for cancer research
• Chemical genetic approaches to the development of cancer therapeutics
• Balancing cell adhesion and Wnt signaling, the key role of β-catenin

back

Src family kinase

• The road to Src
• Structure and regulation of Src family kinases
• Src-family kinases in B-cell development and signaling
• Src in synaptic transmission and plasticity
• Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis
• Molecular interdiction of Src-family kinase signaling in hematopoietic cells
• interplay between Src family kinases and receptor tyrosine kinases
• interplay between Src and integrins in normal and tumor biology
• G-protein-coupled receptors and Src family kinases
• Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation
• Emerging roles for p120-catenin in cell adhesion and cancer
• Crosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways
• Src family kinases,key regulators of signal transduction

back

Tools for tumor target discovery

• VSV-tumor selective replication and protein translation
• Viruses – seeking and destroying the tumor program
• Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer
• SV40 large T antigen targets multiple cellular pathways to elicit cellular transformationv
• Retroviral insertional mutagenesis
• Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus
• Oncolytic viral therapies – the clinical experience
• Oncolytic adenoviruses – selective retargeting to tumor cells
• Modulation of cell function by small transmembrane proteins modeled on the bovine papillomavirus E5 protein
• Meeting product development challenges in manufacturing clinical grade oncolytic adenoviruses
• Involvement of PP2A in viral and cellular transformation
• Inactivating intracellular antiviral responses during adenovirus infection
• Future prospects for oncolytic therapy
• Development of transcriptionally regulated oncolytic adenoviruses
• To replicate or not to replicate-achieving selective oncolytic virus replication in cancer cells through translational control
• Viruses-ools for tumor target discovery, and agents for oncolytic therapies – an introduction

back

RNAi与Cancer

• Using RNAi to catch Drosophila genes in a web of interactions
• Use of RNA interference libraries to investigate oncogenic signalling in mammalian cells
• Towards full employment-using RNAi to find roles for the redundant
• RNAi in a postmodern, postgenomic era
• RNA-interference-based functional genomics in mammalian cells
• RNA interference-based functional genomics in cancer research
• Oncology studies using siRNA libraries
• impact on cancer research
• High-throughput gene silencing using cell arrays
• Genomic instability and cancer
• exploring cancer by systematic loss-of-function

back

肿瘤与AKT信号传递

• The Akt of translational control
• Regulation of the Akt kinase by interacting proteins
• PTEN joins the nuclear crew
• Perturbations of the AKT signaling pathway in human cancer
• linking growth and energy signaling pathways with human disease
• FOXO transcription factors at the interface between longevity and tumor suppression
• Epithelial–mesenchymal transition in development and cancer
• Akt-regulated pathways in prostate cancer
• Akt-PKB pathway-molecular target for cancer drug discovery
• Akt-dependent transformation
• AKT signaling in normal and malignant cells
• AKT crystal structure and AKT-specific inhibitors
• AKT signaling

back

3D Cultures

• Three-dimensional tissue culture models in cancer biology
• Three-dimensional co-culture models to study prostate cancer growth, progression, and metastasis to bone
• Stromagenesis-The changing face of fibroblastic microenvironments during tumor progression
• Matrigel-Basement membrane matrix with biological activity
• In vitro and in vivo imaging of cell migration
• Engineering three-dimensional culture models of breast architecture, function, and neoplastic transformation
• Designer self-assembling peptide nanofiber scaffolds for 3D tissue cell cultures
• A growing case for three-dimensional (3D) culture systems
• 3D-extravasation model – selection of highly motile and metastatic cancer cells
• 3D Cultures

back

Tumor metabolome

• The study of metabolic pathways in tumors based on the transcriptome
• Pyruvate kinase type M2 and its role in tumor growth and spreading
• Plasma free amino acid profile in cancer patients
• Inducible nitric oxide synthase (iNOS) in tumor biology
• Cyclin E as a prognostic and predictive marker in breast cancer
• Arginine deprivation and metabolomics
• Amino acid transporters ASCT2 and LAT1 in cancer
• “Tumor metabolome”-A post-modern genomic view on the role of low molecular weight substances in cancerous cell growth. An introduction

back

Hodgkin's disease

• Twenty-five years clinical trials of the German Hodgkin Study
• the treatment of Hodgkin's disease in the elderly
• The radiotherapy reference panel
• The EORTC strategy in the treatment of Hodgkin's lymphoma
• Special issues in pediatric Hodgkin's disease
• role of radiation therapy in the treatment of Hodgkin's disease
• role of allogeneic stem-cell transplantation in Hodgkin's disease
• Pathogenesis of Hodgkin's lymphoma
• Non-mediastinal grey zone lymphomas
• Lymphocyte-predominant and classical Hodgkin's lymphoma
• International harmonization of trial parameters in malignant lymphoma
• Immunotherapy of Hodgkin's lymphoma
• How to define intermediate stage in Hodgkin's lymphoma
• Hodgkin lymphoma
• Genetic susceptibility to Hodgkin's lymphoma
• Developing new drugs for the treatment of lymphoma
• Current treatment strategies of the German Hodgkin Study Group
• CT and MR imaging in Hodgkin's disease
• chemotherapy alone in patients with limited stage Hodgkin's lymphoma
• Autologous transplantation in relapsed and refractory Hodgkin's disease
• Overview of the Sixth International Symposium on Hodgkin’s disease – recent advances in basic and clinical trials

back

Malignant melanoma

• Integrin signaling in malignant melanoma
• Immunological detection of altered signaling molecules involved in melanoma development
• Functional and therapeutic significance of Akt deregulation in malignant melanoma
• De-regulation of ubiquitin-dependent proteolysis and the pathogenesis of malignant melanoma
• Bone morphogenetic proteins in melanoma

back

Lung cancer

• The treatment of advanced non-small cell lung cancer
• Role of adjuvant chemotherapy in the treatment of non-small-cell
• Preoperative assessment for lung cancer surgery
• New approaches to the minimally invasive treatment of lung cancer
• Management of malignant pleural effusions
• Lung cancer screening
• Interventional pulmonology techniques for treating malignant large airway obstruction
• Innovative bronchoscopic diagnostic techniques
• Identification of Bronchioalveolar Stem Cells in Normal Lung and Lung Cancer
• High-resolution genomic profiles of human lung cancer
• genetics of risk and advances in chemoprevention
• Editorial introductions
• DNA methylation disturbances as novel therapeutic target in lung cancer

back

肿瘤生长的Targeting key pathways

• Targeting key pathways in tumour growth and development
• Role of novel targeted therapies in the clinic
• Targeted antitumour therapy-future perspectives
• The realisation of targeted antitumour therapy
• ZD6474-a novel inhibitor of VEGFR and EGFR tyrosine kinase activity
• ZD6474-clinical experience to date

back

Matrix metalloproteases and cancer

• the control of tumor cell invasion
• Tadpole collagenase, the single parent of such a large family
• Role of matrix metalloproteinases in melanoma cell invasion
• Regulation of matrix metalloproteinase (MMP) activity by the low-density lipoprotein receptor-related protein
• MMP-2, TIMP-2, and type-I collagen levels in human lung carcinoma
• MMP modulator in cancer, development and tissue repair
• From a unique cell to metastasis is a longway to go-clues to stromelysin-3 participation
• Membrane type-matrix metalloproteinases and tumor progression
• Matrikines in the regulation of extracellular matrix degradation
• Hydroxamate-based peptide inhibitors of matrix metalloprotease
• Gelatinases (MMP-2 and-9) and their natural inhibitors as prognostic indicators in solid cancers
• Future challenges facing the development of specific active-site-directed synthetic inhibitors of MMPs
• Functional imaging of pericellular proteolysis in cancer cell invasion
• Crystal structures of MMPs in complex with physiological and pharmacological inhibitors
• Collagenases in cancer
• Beneficial and detrimental influences of tissue inhibitor of metalloproteinase-1 (TIMP-1) in tumor progression
• Assays of matrix metalloproteinases (MMPs) activities
• Matrix metalloproteases and cancer

back

Tumor microenvironment

• Tissue homeostasis and the control of the neoplastic phenotype in epithelial cancers
• The role of the stromal microenvironment in prostate cancer
• Origins and selection of p53 mutations in lung carcinogenesis
• Microenvironmental control of premalignant disease
• Integrative radiation carcinogenesis
• Expanding fields of genetically altered cells in head and neck squamous carcinogenesis
• Colonization of adjacent stem cell compartments by mutant keratinocytes
• Cathepsin B and tumor proteolysis
• tumor microenvironment

back

Lymphocyte development and Tumour immunology

• γδ T cell development — having the strength to get there
• The role of tumor stroma in the interaction between tumor and immune system
• The role of self-peptides in the development of CD4+ CD25+ regulatory T cells
• The importance of mucosal immunity in defense against epithelial cancers
• Receptor signals and nuclear events in CD4 and CD8 T cell lineage commitment
• Migration of dendritic cell based cancer vaccines
• Lymphoid progenitors and primary routes to becoming cells of the immune system
• lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy
• Immunotherapy of cancer through targeting of minor histocompatibility antigens
• Fate and function of lymphoid tissue inducer cells
• Exploitation of the weapon of immune destruction for cancer therapy
• Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer
• Distinguishing features of developing natural killer cells
• Developmental program of mouse Vα14i NKT cells
• Dendritic-cell-based therapeutic vaccination against cancer
• Controlling the thymic microenvironment
• Breaking tolerance in cancer immunotherapy

back

Kinases in Cancer

• TARGETING THE MITOGEN-ACTIVATED PROTEIN KINASE CASCADE TO TREAT CANCER
• STRATEGIES TO OVERCOME RESISTANCE TO TARGETED PROTEIN KINASE INHIBITORS
• REGULATION OF THE CYTOSKELETON-AN ONCOGENIC FUNCTION FOR CDK INHIBITORS-
• NETRIN-1 AND ITS RECEPTORS IN TUMORIGENESIS
• GEFITINIB-A NOVEL TARGETED APPROACH TO TREATING CANCER
• DEVELOPMENT OF TGF-β SIGNALLING INHIBITORS FOR CANCER THERAPY
• AURORA-KINASE INHIBITORS AS ANTICANCER AGENTS

back

Modern Criteria to Identify Human Carcinogens

• The epigenetics of cancer etiology
• Role and limitations of epidemiology in establishing a causal association
• Multistep and multifactorial carcinogenesis
• Modern criteria to determine the etiology of human carcinogens
• Inflammation as a tumor promoter in cancer induction
• Infectious agents and cancer
• Genetic alterations and DNA repair in human carcinogenesis
• Environmental and chemical carcinogenesis
• Current criteria to establish human carcinogens
• Modern criteria to establish human cancer etiology

back

Microenvironmental Regulation of Tumor Development

• Tissue homeostasis and the control of the neoplastic phenotype in epithelial cancers
• The role of the stromal microenvironment in prostate cancer
• Origins and selection of p53 mutations in lung carcinogenesis
• Microenvironmental control of premalignant disease
• Membrane stabilization by intimate contact between cells reduces their Mg2+ activity and suppresses the neoplastic phenotype
• Integrative radiation carcinogenesis
• Expanding fields of genetically altered cells in head and neck squamous carcinogenesis
• Colonization of adjacent stem cell compartments by mutant keratinocytes
• Cathepsin B and tumor proteolysis
• Microenvironmental Regulation of Tumor Development

back

Polo-like kinases

• Yeast polo-like kinases
• The Plk3-Cdc25 circuit
• Structure and function of Polo-like kinases
• Sak-Plk4 and mitotic fidelity
• Regulation of cell cycle checkpoints by polo-like kinases
• Polo-like kinases in the nervous system
• Polo-like kinases and oncogenesis
• Polo-like kinases (Plks) and cancer
• Polo-like kinase Plx1
• Polo kinase and progression through M phase
• Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues
• Polo-like kinases, an introduction

back

Cell-Molecular and cellular themes in cancer research

• Wnt signalling and the mechanistic basis of tumour development
• What have animal models taught us about the p53 pathway
• The pathophysiology of HOX genes and their role in cancer
• novel strategies for defining the origin of tumours
• New approaches for modelling cancer mechanisms in the mouse
• Molecular mechanisms of drug resistance
• Molecular evolution of breast cancer
• Insulin-like growth factor ligands, receptors, and binding proteins in cancer
• Gastrointestinal lymphoma-where morphology meets molecular biology
• Dormant hypermethylated tumour suppressor genes
• Cell-cycle-dependent regulation of DNA replication and its relevance to cancer pathology
• Cell and tissue responses to genotoxic stress
• Advances in imaging mouse tumour models in vivo
• Molecular and cellular themes in cancer research

back

Cancer etiology

• The epigenetics of cancer etiology
• Role and limitations of epidemiology in establishing a causal association
• Multistep and multifactorial carcinogenesis
• Modern criteria to establish human cancer etiology
• Modern criteria to determine the etiology of human carcinogens
• Inflammation as a tumor promoter in cancer induction
• Infectious agents and cancer
• Genetic alterations and DNA repair in human carcinogenesis
• Environmental and chemical carcinogenesis
• Current criteria to establish human carcinogens

back

RNAi

• Using RNAi to catch Drosophila genes in a web of interactions-insights into cancer research
• Use of RNA interference libraries to investigate oncogenic signalling in mammalian cells
• Tumour suppressors-Ever-decreasing effects
• Towards full employment-using RNAi to find roles for the redundant
• Silencing of hdm2 oncogene by siRNA inhibits p53-dependent human breast cancer
• RNA-interference-based functional genomics in mammalian cells
• RNAi in a postmodern, postgenomic era
• RNAi and HTS-exploring cancer by systematic loss-of-function
• RNA interference-based functional genomics in cancer research
• RNA interference-based functional genomics in cancer research-an introduction
• RNA interference is a functional pathway with therapeutic potential in human myeloid leukemia
• Reversal of P-glycoprotein-mediated multidrug resistance with small interference RNA in leukemia
• Oncology studies using siRNA libraries
• New tools for functional mammalian cancer genetics
• High-throughput gene silencing using cell arrays
• glycoprotein-mediated multidrug resistance in human gastric carcinoma cells by RNA interference
• Genomic instability and cancer-scanning the Caenorhabditis elegans genome for tumor suppressors
• Genome-wide RNAi screens in Caenorhabditis elegans-impact on cancer research
• A vision for the National Cancer Program in the United States

back

Colorectal Cancer

• The Global Challenge of Colorectal Cancer-the screening process
• The Global Challenge of Colorectal Cancer-public education
• The Global Challenge of Colorectal Cancer-professional education and advocacy
• The Global Challenge of Colorectal Cancer-facilitating screening for colorectal cancer
• The Global Challenge of Colorectal Cancer-criteria for screening
• The Global Challenge of Colorectal Cancer
• Pharmacogenomics and colorectal cancer
• A functional polymorphism (-347 G-GA) in the E-cadherin gene is associated with colorectal cancer
• The role of uracil-tegafur (UFT) in elderly patients with colorectal cancer
• Predictive factors for response to chemotherapy in colorectal cancer patients
• New options and old dilemmas in the treatment of patients with advanced colorectal cancer
• GENETIC PREDISPOSITION TO COLORECTAL CANCER
• Effect of physician recommendation and patient adherence on rates of colorectal cancer testing
• Treatment and Referral Patterns for Colorectal Cancer.
• Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening comparison with an immunochemical test for occult blood
• Expression of epidermal growth factor-receptor related protein (ERRP) in human colorectal carcinogenesis
• Estimation of the familial relative risk of cancer by site from a French population based family study on colorectal cancer
• Current Status of Laparoscopic Resection for Colorectal Cancer.
• Public awareness of risk factors and screening for colorectal cancer in Europe
• Predictive Factors for Lymph Node Metastasis in T1 Stage Colorectal Carcinomas
• Loss of Heterozygosity and Mutational Analyses of the ACTRII Gene Locus in Human Colorectal Tumors
• Decreased interleukin-1 receptor antagonist response following moderate exercise in patients with colorectal carcinoma after primary treatment
• Treatment of colorectal cancer metastasis
• Surgical treatment of colorectal cancer metastasis
• Role of matrix metalloproteinases (MMPs) in colorectal cancer
• Role of cyclooxygenase-2 in colorectal cancer
• Mucins and mucin binding proteins in colorectal cancer
• Matrix metalloproteinases in colorectal cancer
• Lymphoid enhancer factor-T cell factor expression in colorectal cancer
• Epigenetic changes in colorectal cancer
• Current and future trends in colorectal cancer screening
• ck-TGFβ and Wnt pathway cross-talk
• Colorectal Cancer
• Therapeutic Strategies For Metastatic Colorectal Cancer
• The Role Of Total Mesorectal Excision In The Management Of Rectal Cancer
• Methods And Results Of Sphincter-Preserving Surgery For Rectal Cancer
• Metastatic Colorectal Cance-Systemic Treatment In The New Millennium
• Lympca-Colorectal Cancer-Hatic Mapping And Sentinel Node Analysis To Optimize Laparoscopic Resection And Staging Of Colorectal Cancer-An Update
• Current And Evolving Strategies For Colorectal Cancer Screening
• Loss of IGF2 Imprinting-A Potential Marker of Colorectal Cancer Risk
• Colorectal Cancer Screening-scientific review
• ca-Colorectal Cancer-Colorectal Cancer Screening-Clinical Applications
• Surveillance guidelines after removal of colorectal adenomatous polyps
• Screening guidelines for colorectal cancer and polyps
• Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients
• Guidelines for monitoring of patients with ureterosigmoidostomy
• Guidelines for colorectal cancer screening in high risk groups
• Guidance on large bowel surveillance for people with two first degree relatives with colorectal cancer
• Guidance on gastrointestinal surveillance for hereditary non-polyposis colorectal cancer
• Plasminogen System in Colorectal Cancer
• New Strategies for Colorectal Cancer Prevention and Treatment
• Ultrastaging of early colon cancer using lymphatic mapping and molecular analysis
• Treatment of liver metastases, an update on the possibilities and results
• Transanal endoscopic microsurgery for rectal cancer
• The role of radiotherapy in rectal cancer
• The role of pathologists in the quality control of diagnosis and treatment of rectal cancer
• The circumferential margin in rectal cancer
• The APC gene in colorectal cancer
• Systemic treatment of colorectal cancer
• Surgical trials in oncology; the importance of quality control in the TME trial
• Screening for Colorectal Cancer
• Radiology of colorectal cancer
• Prognosis and response to therapy in colorectal cancer
• Patterns of lymphatic spread in rectal cancer
• Past, present and future perspectives of colorectal cancer
• Laparoscopic surgery for colorectal carcinoma
• Insulin, Insulin-Like Growth Factor-I (IGF-I), IGF Binding Proteins, Their Biologic Interactions, and Colorectal Cancer
• Follow-up of patients with colorectal cancer
• Distinction between familial and sporadic forms of colorectal cancer showing DNA microsatellite instability
• Developments and quality assurance in rectal cancer surgery
• Cost-effectiveness analysis of colorectal cancer treatments
• Cancer genetics and their application to individualised medicine
• Biological therapy of colorectal cancer

back

Signal transduction therapy

• The inhibitor of apoptosis protein family (IAPs)
• Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate
• Stress-activated protein kinases—tumor suppressors or tumor initiators
• RNA molecules as anti-cancer agents
• Prenyl-binding domains- potential targets for Ras inhibitors and anti-cancer drugs
• Oncogenic growth factor receptors- implications for signal transduction therapy
• Manipulation of the tumor suppressor p53 for potentiating cancer therapy
• In search of drug treatment for genetic defects in the DNA damage response
• DAP-kinase as a target for drug design in cancer and diseases associated with accelerated cell death
• Signal transduction therapy

back

Inflammation and Cancer

• Inflammation and Cancer V. Chronic pancreatitis and pancreatic cancer
• Inflammation and Cancer V. Chronic pancreatitis and pancreatic cancer
• Inflammation and Cancer IV. Colorectal cancer in inflammatory bowel disease
• Inflammation and Cancer III. Somatostatin and the innate immune system
• Inflammation and Cancer II. Role of chronic inflammation and cytokine gene polymorphisms
• Inflammation and Cancer I. Rodent models of infectious gastrointestinal and liver cancer
• Inflammation and Cancer III
• Inflammation and Cancer II
• Inflammation and Cancer I

back

Chemokines in Neoplastic Progressio

• The significance of cancer cell expression of the chemokine receptor CXCR4
• Regulation of the trafficking of tumour-infiltrating dendritic cells by chemokines
• CXC chemokines in angiogenesis of cancer
• Chemokines in the recruitment and shaping of the leukocyte infiltrate of tumors
• Chemokines in neoplastic progression
• Chemokines and Kaposi’s sarcoma
• Chemokine–protease interactions in cancer
• CCL2 (monocyte chemoattractant protein-1) and cancer
• Cancer immunotherapy with chemoattractant peptides
• Chemokines in Neoplastic Progression

back

Radiation

• The p53 protein family and radiation sensitivity
• The influence of Ras pathway signaling on tumor radiosensitivity
• Radiation-induced neoplastic transformation in vitro
• Radiation cytogenetics
• Radiation and the cell cycle, revisited
• Radiation and hypoxia inducible gene therapy systems
• Opioid peptides in cancer
• Microbeam developments and applications
• Metabolic oxidation-reduction reactions and cellular responses to ionizing radiation
• Is low-dose hyper-radiosensitivity a measure of G2-phase cell radiosensitivity
• Implications of apoptosis regulators in tumorigenesis
• Hypoxic gene expression and metastasis
• Gene expression profiling after irradiation
• Enhanced radiation response through directed molecular targeting approaches
• Basic radiation research into the new millennium
• Basic radiation research into the new millennium
• Aggressive basal cell carcinoma

back

Radiation Research

• The p53 protein family and radiation sensitivity
• reduction reactions and cellular responses to ionizing radiation
• Radiation-induced neoplastic transformation in vitro
• Radiation cytogenetics
• Radiation and the cell cycle
• Radiation and hypoxia inducible gene therapy systems
• Microbeam developments and applications
• Is low-dose hyper-radiosensitivity a measure of G2-phase cell radiosensitivity？
• influence of Ras pathway signaling on tumor radiosensitivity
• Hypoxic gene expression and metastasis
• Gene expression profiling after irradiation
• Enhanced radiation response through directed molecular targeting approaches
• Basic radiation research into the new millennium

back

leukemia

• The diverse superfamily of lysine acetyltransferases and their roles in leukemia
• Optimizing Treatment of Chronic Myeloid Leukemia
• T-Cell Large Granular Lymphocyte Leukemia and Related Disorders
• VEGF and myeloid leukemias
• Crosstalk between angiogenesis and lymphangiogenesis in tumor progression
• Beyond chronic myelogenous leukemia
• Apoptotic mechanisms in the control of erythropoiesis
• Apoptosis in acute leukemia
• Ajoene (natural garlic compound)-a new anti-leukaemia agent for AML therapy
• Acute promyelocytic leukemia
• Adult acute myeloid leukaemia
• Treatment with monoclonal antibodies in acute lymphoblastic leukemia
• Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia
• Cytokines and retinoic acid therapy for APL
• Basic science going clinical-molecularly targeted therapy of chronic myelogenous leukemia
• The best way to use asparaginase in childhood acute lymphatic leukaemia
• Guidelines on the diagnosis and management of chronic lymphocytic leukaemia
• Topoisomerase I inhibitors in the treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia
• therapy-Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia
• thalidomide therapy for myelodysplastic syndromes
• Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia
• Methylation profiling in multiple myeloma
• Gene-Expression Profiling
• Gene-Expression Profiling in Acute Myeloid Leukemia
• Cytokines and retinoic acid therapy for APL
• Current Approach to Diagnosis and Management of Chronic Lymphocytic Leukemia
• Changing picture of cellular drug resistance in human leukemia
• Bim is a suppressor of Myc-induced mouse B cell leukemia
• Angiogenesis in acute and chronic lymphocytic leukemia
• Acute Lymphoblastic Leukemia
• Cells and the Cytokine Network-Therapeutic
• Activation of the Wnt signaling pathway in chronic lymphocytic leukemia
• beneficial actions of retinoids and rexinoids
• Rapid diagnosis of acute promyelocytic leukemia (PML)
• Monitoring treatment efficiency in MDS at the molecular level-possibilities now and in the future
• Chronic myeloid leukemia—still a few questions
• beneficial actions of retinoids and rexinoids
• Array-based analysis of gene expression in childhood acute lymphoblastic leukemia
• beneficial actions of retinoids and rexinoids

back

Melanoma

• The natural course of cutaneous melanoma
  
• The history and future of melanoma staging
  
• Pathology of melanocytic lesions
  
• Mucosal melanoma
  
• Management of lentigo maligna and lentigo maligna melanoma
  
• Lessons learned from the Sunbelt Melanoma Trial
  
• Controversies in the management of metastatic melanoma to regional lymphatic basins
  
• Australian experience in sun protection and screening for melanoma
  

back

New targets for cancer therapy

• New Targets for Antithrombotic Drugs
  
• Anticancer research-a few hints for discovery of new targets
  
• Ceramide synthesis and metabolism as a target for cancer therapy
  
• Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone
  
• From Ras signalling to ChoK inhibitors
  
• Green fluorescent protein as a tool to study epidermal growth factor receptor function
  
• Perspectives on farnesyl transferase inhibitors in cancer therapy
  
• Rho GTPases-potential candidates for anticancer therapy
  
• The IKK-NF-B activation pathway–a target for prevention and treatment of cancer
  

back

The molecular mechanisms underlying cancer

• Aberrant mRNA translation in cancer pathogenesis
  
• An essential role for protein synthesis in oncogenic cellular transformation
  
• Cellular internal ribosome entry segments
  
• eIF4E-from translation to transformation
  
• eIF-4E expression and its role in malignancies and metastases
  
• Postgenomic global analysis of translational control induced by oncogenic signaling
  
• RNA polymerase III transcription and cancer
  
• role of translation in neoplastic transformation from a pathologist's point of view
  
• Signaling control of mRNA translation in cancer pathogenesis
  
• Target of rapamycin (TOR)
  
• Targets and mechanisms for the regulation of translation in malignant transformation
  
• The role of c-myc in regulation of translation initiation
  
• Translational regulation by the p210 BCR-ABL oncoprotein
  

back

Cell death and cancer

• Cell death and cancer
  
• Apoptosis defects and chemotherapy resistance
  
• Autophagy as a cell death and tumor suppressor mechanism
  
• Bcl-2 and calcium
  
• Caspase activation-stepping on the gas or releasing the brakes
  
• Caspase-independent cell death
  
• Cell death by mitotic catastrophe
  
• Death receptors in chemotherapy and cancer
  
• DNA damage-induced apoptosis
  
• Hallmarks of senescence in carcinogenesis and cancer therapy
  
• Lysosomes in cell death
  
• Mitogen-activated protein kinases in apoptosis regulation
  
• Molecular chaperones and the stress of oncogenesis
  
• Multiple cell death pathways as regulators of tumour initiation and progression
  
• PML nuclear bodies and apoptosis
  
• Prospective strategies to enforce selectively cell death in cancer cells
  
• Regulation of the apoptosis-necrosis switch
  
• Role of AIF in caspase-dependent and caspase-independent cell death
  
• Role of mitochondrial membrane permeabilization in apoptosis and cancer
  
• To die or not to die-how does p53 decide
  
• Toxic proteins released from mitochondria in cell death
  

back

Regulation of angiogenesis and tumorigenesis

• Regulation of angiogenesis and tumorigenesis
  
• Antiangiogenic cancer therapy
  
• Autocrine signaling in carcinoma-VEGF and the 64 integrin
  
• Molecular regulation of angiogenesis and tumorigenesis by signal transduction pathways
  
• Multiple regulatory pathways of vascular permeability factor-vascular endothelial growth factor (VPF-VEGF) expression in tumors
  
• Oncogenes and tumor angiogenesis
  
• Oncogenic Ras and its role in tumor cell invasion and metastasis
  
• UVA-mediated activation of signaling pathways involved in skin tumor promotion and progression
  

back

Stroma reaction and cancer progression

• Introduction-Stroma reaction and cancer progression
  
• Tumour invasion and matrix metalloproteinases
  
• TIMPs as multifacial proteins
  
• Thrombospondin 1-a multifunctional protein implicated in the regulation of tumor growth
  
• Stromal reaction in cutaneous melanoma
  
• Matrix metalloproteinases and matrikines in angiogenesis
  
• Involvement of stromal proteoglycans in tumour progression
  
• Elastin as a matrikine
  
• Control of melanoma progression by various matrikines from basement membrane macromolecules
  
• An introduction to matrikines-extracellular matrix-derived peptides which regulate cell activity-Implication in tumor invasion
  
• A novel strategy for designing specific gelatinase A inhibitors
  
• Stroma reaction and cancer progression
  

back

Cancer and Metastasis

• Cancer and Metastasis
  
• The type-1 insulin-like growth factor receptor tyrosine kinase and breast cancer
  
• The role of integrin-linked kinase (ILK) in cancer progression
  
• The Aurora kinases-Role in cell transformation and tumorigenesis
  
• Src family kinases in tumor progression and metastasis
  
• Role of MAP kinase in tumor progression and invasion
  
• Regulators of G1 cyclin¨Cdependent kinases and cancers
  
• p21-activated kinases in human cancer
  
• Jak family of kinases in cancer
  
• Intraperitoneal cancer dissemination-Mechanisms of the patterns of spread
  
• FAK regulates biological processes important for the pathogenesis of cancer---
  
• EGF receptor family tyrosine kinases as signal integrators and therapeutic targets
  
• Deregulation of NF-|êB and its upstream kinases in cancer
  
• c-Met-Structure, functions and potential for therapeutic inhibition
  
• Cancer and Metastasis
  

back

Microarrays and Cancer

• Statistical Modeling And Visualization Of Molecular Profiles In Cancer
  
• Qa-Qc As-Pressing Need For Microarray Analysis-Meeting Report
  
• Open Source Software For The Analysis Of Microarray Data
  
• Microarrays In Cancer-Research And Applications
  
• Microarray-Based Cancer Diagnosis With Artificial Neural Networks
  
• Gene Expression Databases And Data Mining
  
• From Correlation To Causality-Microarrays, Cancer, And Cancer Treatment
  
• Experimental Design Of Dna Microarray Experiments
  
• Commercial Aspects Of Microarray Technology
  
• Assessing The Functional Bias Of Commercial Microarrays Using The
  
• Microarrays And Cancer
  
• Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays
  
• Epidemiology, cancer genetics and microarrays-making correct inferences, using appropriate designs
  
• Molecular Profiling Of The Immune Response In Colon Cancer Using Protein Microarrays
  
• Signal Pathway Profiling Of Cancer Using Reverse-Phase Protein Microarrays
  
• High-Thoughput Proteomics-Using Protein Microarrays To Study Cancer
  
• Microarrays Of Tumor Cell Derived Proteins Uncover A Distinct Pattern Of Prostate Cancer Serum Immunoreactivity
  
• Methods And Applications Of Antibody Microarrays In Cancer Research
  

back

Clinical Guidelines-Cancer

• Recommendations For The Management Of Patients With Non-Small-Cell Lung Carcinoma
  
• Standards, Options And Recommendations For Malnutrition And Nutritional Assessment In Patients With Cancer
  
• The Use Of Positron Emission Tomography With 2-[18f]Fluoro-2-Deoxy-D-Glucose (Fdp-Pet Scanning) In Oncology
  
• Using Service Guidance To Shape The Delivery Of Cancer Services-Experience In The Uk
  
• Project-An Evidence-Based Patient Information And Education Project
  
• Standards, Options And Recommendations For Nutritional Support In Patients Undergoing Bone Marrow Transplantation
  
• Standards, Options And Recommendations For Palliative Or Terminal Nutrition In Adults With Progressive Cancer
  
• Standards, Options And Recommendations For The Management Of Patients With Nonmetastatic Prostate Cancer
  
• Standards, Options And Recommendations For The Use Of Appetite Stimulants In Oncology
  
• Standards, Options And Recommendations For The Management Of Adult Patients With Intracranial Glioma
  
• Standards, Options And Recommendations For The Management Of Patients With Carcinoma Of Unknown Primary Site
  
• Towards Better Quality Guidelines And Increased International Collaboration
  
• Recommendations For The Use Of Analgesia For The Treatment Of Nociceptive Pain In Adults With Cancer
  
• Summary Report Of The Standards, Options And Recommendations For The Use Of Serum Tumour Markers In Breast Cancer
  
• Patient Information And Shared Decision-Making In Cancer Care
  
• Clinical Guidelines
  
• Summary Version Of The Standards, Options And Recommendations For Nonmetastatic Breast Cancer
  
• Nice Cancer Guidance-A Description Of The Institute’s Clinical Guideline Programme
  
• Perspectives on the Value of American Society of Clinical Oncology Clinical Guidelines
  

back

Cellular Stress And Cancer

• The Rad30 Cancer Susceptibility Gene
  
• Sister Chromatid Cohesion And Genome Stability In Vertebrate Cells
  
• Role Played By Brca1 In Regulating The Cellular Response To Stress
  
• Role Of The Saccharomyces Cerevisiae Rad9 Protein In Sensing And Responding To Dna Damage
  
• Regulation Of Eukaryotic Dna Replication At The Initiation Step
  
• Protein–protein Interactions During Mammalian Dna Single-Strand Break Repair
  

back

Myeloid Biology

• Update In Childhood Acute Myeloid Leukemia
  
• Structure, Organization, And Function Of Glycosphingolipids In Membrane
  
• Role Of Neutrophil Elastase In Bone Marrow Failure Syndromes Molecular Genetic Revival Of The Chalone Hypothesis
  
• Role Of Constitutively Activated Protein Tyrosine Kinases In Malignant Myeloproliferative Disorders
  
• Regulation Of Neutrophil Function By Rac Gtpases
  
• Px Domain Takes Shape
  
• Neutrophil Transendothelial Migration And Neutrophil-Derived Azurocidin
  
• Genetic Basis Of Fanconi Anemia
  
• Current Challenges In Therapy Of Myelodysplastic Syndromes
  
• Myeloid Biology
  

back

Carcinogenesis Bioassays and Protecting

• Asbestos Fibers Contributing to the Induction of Human Malignant Mesothelioma
  
• Carcinogenic Effects of Benzene
  
• Carcinogenicity and Mechanistic Insights on the Behavior of Epoxides and Epoxide-Forming Chemicals
  
• Carcinogenicity of Methyl-Tertiary Butyl Ether in Gasoline
  
• Chemicals Studied and Evaluated in Long-Term Carcinogenesis Bioassays by Both the Ramazzini Foundation and the National Toxicology Program
  
• Primary Prevention Protects Public Health
  
• Ramazzini Foundation Cancer Program- History and Major Projects, Life-Span Carcinogenicity Bioassay
  
• Remembering Professor Cesare Maltoni
  
• Results of Long-Term Carcinogenicity Bioassay on Vinyl Acetate Monomer
  
• Results of Long-Term Carcinogenicity Bioassays on Tert-Amyl-Methyl-Ether (TAME) and Di-Isopropyl-Ether (DIPE)
  
• Results of Long-Term Experimental Studies on the Carcinogenicity of Ethylene-bis-Dithiocarbamate (Mancozeb)
  
• Results of Long-Term Experimental Studies on the Carcinogenicity of Formaldehyde and Acetaldehyde
  
• Results of Long-Term Experimental Studies on the Carcinogenicity of Methyl Alcohol and Ethyl Alcohol
  
• The National Toxicology Program Rodent Bioassay
  
• Epithelial carcinogenesis- challenging monoclonality
  

  back

Early Detection of Cancer

• Ultrasound Screening for the Early Detection of Ovarian Cancer
  
• cancer early detection
  
• PROTEOMIC APPLICATIONS FOR THE EARLY DETECTION OF CANCER
  
• THE CASE FOR EARLY DETECTION-
  
• THE POWER AND THE PROMISE OF DNA METHYLATION MARKERS
  
• Tumor markers for the early detection of bladder cancer
  
• surg-Early detection of colorectal cancer using high-magnification chromoscopic colonoscopy
  
• Epigenetics in cancer-implications for early detection and prevention
  
• Lung cancer in Europe in 2000-epidemiology, prevention, and early detection
  
• pancreatic cancer-The MUC gene family-Their role in diagnosis and early detection of pancreatic cancer
  
• Prostate Specific Antigen and Human Glandular Kallikrein 2 in Early Detection of Prostate Cancer
  
• American Cancer Society Guidelines for the Early Detection of Cancer
  
• American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer
  
• Prevention and Early Detection Clinical Trials
  

  back

Genetic & Epigenetic Contributions to Tumor Evolution

• ca-genetic and epigenetic contributions to tumor evolution-
  
• BRCA1 methylation- a significant role in tumour development
  
• DNA methylation and genomic imprinting- insights from cancer into epigenetic mechanisms
  
• DNA methylation changes in leukaemia
  
• Epigenetic versus genetic alterations in the inactivation of E-cadherin
  
• Epigenetics wins over genetics- induction of differentiation in tumor cells
  
• Mechanisms underlying epigenetically mediated gene silencing in cancer
  
• Role of genetic and epigenetic changes in Burkitt lymphoma
  
• The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer
  

  back

Antitumor Immunity

• antitumor immunity and tumor progression
  
• Cell–matrix interactions in cancer spreading
  
• Dendritic cells, antigen distribution and the initiation of primary immune responses to self and non-self antigens
  
• Early phenotypic changes of in vitro transformed cells during in vivo progression- possible role of the host innate immunity
  
• Fibronectin in malignancy
  
• Implication of direct host–tumor intercellular interactions in non-immune host resistance to neoplastic growth
  
• Interleukin-1––a major pleiotropic cytokine in tumor–host interactions
  
• Laminin isoforms in tumor invasion, angiogenesis and metastasis
  
• Matrix-directed regulation of pericellular proteolysis and tumor progression
  
• Mechanisms of immune privilege for tumor cells by regulatory cytokines produced by innate and acquired immune cells
  
• Proteoglycans and tumor progression
  
• Role of elastin–matrix interactions in tumor progression
  
• The biological role of the Fas-FasL system during tumor formation and progression
  
• Tumor progression- a brief historical perspective
  
• associated antigens following dendritic cell vaccination of cancer patients
  

  back

Apoptosis & Cancer

• Apoptosis and cancer-lung-A review
  
• Apoptosis and cancer-melanoma
  
• Angiogenesis and apoptosis
  
• Apoptosis and cancer-where we are and where to go
  
• Apoptosis in hematological disorders
  
• Apoptosis, proliferation, differentiation
  
• Cell surface Death Receptor signaling in normal and cancer cells
  
• Defects in the apoptotic machinery of cancer cells
  
• NF-B in cancer- a marked target
  
• Restoring apoptosis as a s